Axovant Sciences Ltd (NYSE:AXON) has been given an average recommendation of “Buy” by the twelve analysts that are covering the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $28.69.

Several research firms recently issued reports on AXON. Piper Jaffray Companies reissued an “overweight” rating and set a $32.00 price objective on shares of Axovant Sciences in a research note on Wednesday, April 12th. Jefferies Group LLC reissued a “buy” rating and set a $31.00 price objective on shares of Axovant Sciences in a research note on Tuesday, April 18th. Oppenheimer Holdings Inc. lifted their price objective on Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a research note on Monday, April 17th. CIBC lifted their price objective on Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a research note on Tuesday, April 18th. Finally, Cowen and Company began coverage on Axovant Sciences in a research note on Friday, February 3rd. They set an “outperform” rating and a $22.00 price objective for the company.

In other news, insider David Hung bought 539,375 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The shares were purchased at an average price of $18.54 per share, for a total transaction of $10,000,012.50. Following the acquisition, the insider now owns 539,375 shares of the company’s stock, valued at $10,000,012.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director W Anthony Vernon bought 53,937 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The shares were purchased at an average price of $18.54 per share, for a total transaction of $999,991.98. Following the acquisition, the director now directly owns 53,937 shares in the company, valued at approximately $999,991.98. The disclosure for this purchase can be found here. 3.10% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA increased its position in Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the period. Janus Capital Management LLC boosted its stake in shares of Axovant Sciences by 5.9% in the fourth quarter. Janus Capital Management LLC now owns 4,679,224 shares of the biotechnology company’s stock worth $58,121,000 after buying an additional 261,097 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares in the last quarter. C WorldWide Group Holding A S bought a new stake in shares of Axovant Sciences during the first quarter worth approximately $1,637,000. Finally, Highbridge Capital Management LLC bought a new stake in shares of Axovant Sciences during the third quarter worth approximately $1,057,000.

Shares of Axovant Sciences (NYSE:AXON) opened at 22.20 on Friday. The company’s 50 day moving average price is $21.01 and its 200 day moving average price is $15.06. The company’s market capitalization is $2.20 billion. Axovant Sciences has a 12 month low of $10.69 and a 12 month high of $25.18.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/19/axovant-sciences-ltd-axon-given-consensus-recommendation-of-buy-by-brokerages.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.